Neil Abdollahian

Neil Abdollahian brings over 20 years of experience in the biotech industry in corporate strategy and business development execution, closing a wide variety of transactions including in- and out-licensing deals, research collaborations and M&A transactions.

Prior to Boundless Bio, he served as Chief Business Officer at Cidara Therapeutics where he led strategic initiatives that resulted in transformational partnerships, including both product and platform deals, with Janssen Pharmaceuticals and MundiPharma.

Prior to Cidara, Neil was Managing Director of Clarity Point Partners, a strategic advisory firm focused on corporate development initiatives including product acquisitions and licensing for biopharmaceutical companies. From 2008 to 2013, he served as Vice President of Corporate Development at Trius Therapeutics, where he led the corporate partnering initiatives that resulted in the Asia-Pacific and emerging markets strategic partnership with Bayer Healthcare, and ultimately, the acquisition by Cubist Pharmaceuticals. Before Trius, Neil served as Director of Special Projects in a biopharmaceutical focused investment bank in Sydney, Australia, and prior to that he held various business development positions focused on closing high-value transactions while at Avanir Pharmaceuticals, Ionis (formerly Isis) Pharmaceuticals and Neurogen Corporation.

He holds an MBA from Pepperdine University, an M.S. in the biomedical sciences from the University of New Mexico Medical School and a B.S. in biology from George Washington University.